FOLFIRINOX + Oxaliplatin + Leucovorin + Irinotecan + 5-Fluorouracil (5-FU) + NIS793 + Capecitabine
Phase 1Terminated 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreas Cancer
Conditions
Pancreas Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
Trial Timeline
Aug 9, 2022 → Jul 10, 2023
NCT ID
NCT05417386About FOLFIRINOX + Oxaliplatin + Leucovorin + Irinotecan + 5-Fluorouracil (5-FU) + NIS793 + Capecitabine
FOLFIRINOX + Oxaliplatin + Leucovorin + Irinotecan + 5-Fluorouracil (5-FU) + NIS793 + Capecitabine is a phase 1 stage product being developed by Novartis for Pancreas Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT05417386. Target conditions include Pancreas Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma.
What happened to similar drugs?
1 of 5 similar drugs in Pancreas Cancer were approved
Approved (1) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
6
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05417386 | Phase 1 | Terminated |
Competing Products
20 competing products in Pancreas Cancer